Answer to the question
No â the press release only covered the Q2âŻ2025 results and a general business update. It did not include any forwardâlooking guidance for Q3âŻ2025 earnings or cashâflow, nor for the fullâyear 2025 period.
Trading implications
Fundamental view: With no guidance, the market still has limited visibility on the companyâs nearâterm profitability trajectory. Investors should focus on the disclosed Q2 metrics (revenue, R&D spend, cash balance) and the companyâs pipeline milestones to gauge upside potential. The absence of guidance can be interpreted as a neutral signal, but it also leaves room for surpriseâeither positive if upcoming data readâouts exceed expectations, or negative if cashâburn remains high.
Technical perspective: ADIL has been trading in a relatively tight range around its recent lows, reflecting the uncertainty around future cashâflow. Until the next guidance or a major clinical data release, the stock is likely to remain supportâbound. A breakout above the recent resistance (~$2.30) on any positive catalyst (e.g., a promising PhaseâŻ2 readâout) could trigger shortâterm buying, while a breach below the current support (~$1.80) may signal further downside as investors price in higher cashâburn.
Actionable insight: Maintain a watchâlist position (e.g., a smallâsize long or a tight stopâloss) until the company issues its Q3 or fullâyear guidance, or until a substantive clinical milestone is announced. In the meantime, monitor cashâburn trends and any forwardâlooking statements in subsequent earnings calls for early signs of guidance. If the company unexpectedly raises guidance, a quick upside move can be captured; if guidance remains absent and cashâburn escalates, consider a defensive tilt or a stopâloss near the current support level.